I don't know when they plan on buying back more stock Aurum, but they did say at earnings that there was no stock purchased during the 3rd quarter. Again, all eyes right now are on December 11th, while I am optimistic I am cautiously so. I am really hoping Levin has something bold and fresh to say. With the stock price back under $40 it appears it will take nothing short of a miracle to get us out of this fix. It appears Copaxone (while it continues to produce great numbers for Teva) is treated like a curse, since it represents such a big part revenue and it will eventually go away once the other competition is ready to come out. I believe it has been grossly overdone, but obviously the market does not think so and thats what counts.
Perhaps TEVA thinks it has better use for the money or perhaps they think the shares will get cheaper. I'm very disappointed in the way this stock has acted. I believe generics are a good place to be in but Mylan appears to be running on all cylinders while TEVA is in reverse.